|
|
Effect of family pharmacist service model on patients with stable chronic obstructive pulmonary disease |
XU Hui RUAN Weifeng▲ MA Tianhong LI Liang FAN Xiaoliang |
Department of Pharmacy, Jiaxing Traditional Chinese Medicine Hospital, Zhejiang Province, Jiaxing 314000, China
|
|
|
Abstract Objective To explore the effect of family pharmacist service model on patients with stable chronic obstructive pulmonary disease (COPD). Methods A total of 80 COPD patients with grade B and C of global initiative for COPD were selected from Jiaxing Traditional Chinese Medicine Hospital, Zhejiang Province from April 2019 to March 2020, and they were divided into observation group and control group according to random number table method, with 40 patients in each group. The observation group received the family pharmacist service, and the control group received routine medical treatment. Both groups were followed up for one year. The scores of medication compliance, St. George’s respiratory questionnaire (SGRQ), COPD assessment test (CAT) before and after intervention were compared between the two groups, and the differences in acute exacerbations between the two groups were compared. Results In the observation group, four cases were lost to follow-up, and 36 cases were finally included. In the control group, two cases were lost to follow-up, and 38 cases were finally included. After intervention, the medication compliance scores of both groups were higher than those before intervention, and those of observation group were higher than those of control group, the differences were statistically significant (P<0.05). After intervention, the scores of SGRQ, CAT, and acute exacerbations in two groups were lower than those before intervention, and those of observation group were lower than those of control group, the differences were statistically significant (P<0.05). Conclusion The family pharmacist service model can effectively improve the medication compliance of patients with stable COPD, promote the rational and standardized drug use of patients, and the clinical application of value.
|
|
|
|
|
[1] Wang C,Xu JY,Yang L,et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study):a national cross-sectional study [J]. Lancet,2018,391(10131):1706-1717.
[2] 李凡,孙惠芬,段静,等.从GOLD指南的演变看慢性阻塞性肺疾病的防治[J].中国全科医学,2019,22(27):3275-3280.
[3] 李凡,盛春风,王欢英.提高全科医生在慢性病早期诊断和管理中的地位和作用——以慢性阻塞性肺疾病为例[J].中国全科医学,2021,24(9):1044-1050.
[4] 陈亚红.2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J].中国医学前沿杂志(电子版),2019,11(1):1-14.
[5] Sulaiman I,Cushen B,Greene G,et al. Objective assessment of adherence to inhalers by COPD patients [J]. Am J Respir Crit Care Med,2017,195(10):1333-1343.
[6] 吴晓玲,谢奕丹,邱宇翔,等.家庭药师制度的构建与实践探索[J].今日药学,2018,28(5):340-348.
[7] 中华人民共和国卫生部.慢性阻塞性肺疾病诊断标准[J].国际呼吸杂志,2011,31(1):1-2.
[8] 姚剑坤,李翠君,欧阳细瑜,等.布地格福吸入气雾剂联合肺康复训练对中重度慢阻肺患者的影响[J].中国实用医药,2022,17(6):29-32.
[9] 李正欢,张晓云,陈杨,等.基于2021年GOLD《COPD诊断、治疗与预防全球策略》解析慢性阻塞性肺疾病稳定期非药物管理策略[J].中国全科医学,2022,25(2):131-138.
[10] Singh D,Agusti A,Anzueto A,et al. Global Strategy for the Diagnosis,Management,and Prevention of Chronic Obstructive Lung Disease:the GOLD science committee report 2019 [J]. Eur Respir J,2019,53(5):1900164.
[11] 都勇,刘姜红,王爱平.慢性气道疾病患者吸入治疗依从性的现状及影响因素研究[J].中国实用护理杂志,2021,37(5):326-335.
[12] 杨丽芬,杨添文,任朝凤,等.督导戒烟对吸烟慢性阻塞性肺疾病患者CAT、mMRC、SGRQ评分及再入院风险的随机对照研究[J].中国呼吸与危重监护杂志,2021, 20(11):761-767.
[13] 孔苗苗.综合评估及干预策略影响稳定期老年慢阻肺患者急性加重次数及肺功能的临床研究[D].扬州:扬州大学,2021.
[14] 张启龙,马艳梅,马红红,等.顺尔宁联合信必可都保对老年稳定期慢性阻塞性肺疾病患者的应用效果分析[J].河北医学,2022,28(6):1002-1006.
[15] 潘子涵,迟春花,郑家强.基层医疗机构慢性阻塞性肺疾病筛查方法研究现状[J].中国全科医学,2020,23(3):257-266.
[16] 马菲菲,史亮.莫西沙星治疗COPD合并呼衰对患者肺功能氧代谢及血清CRP CK LDH NBC水平的影响[J].河北医学,2021,27(6):896-901.
[17] 王志辉,季敏,孙子杭,等.药师参与家庭医师团队开展药学服务的模式探讨[J].中国医院用药评价与分析,2018,18(2):276-279.
[18] 张磊,李浩.临床药师引导住院患者参与用药安全的模式及应用评价[J].中国医药科学,2023,13(8):126-128, 145.
[19] 易媛,徐志旸,刘海艳,等.药师用药指导联合家庭参与管理模式对精神分裂症患者依从性及疗效的影响[J].中国医药科学,2022,12(16):101-104.
[20] 吴晓玲,于国超.家庭药师服务标准与路径专家共识[J].药品评价,2018,15(16):4-16.
[21] 高洋洋,郭毅,王世燕,等.药师用药交代与指导服务能力提升的实践与探讨[J].华西药学杂志,2021,36(2):233-236.
[22] 谢跃辉,袁琴,杨悟新.药师参与对慢性阻塞性肺疾病患者治疗依从性及疗效的影响[J].中国当代医药,2021,28(12):18-21.
[23] 张超,韩家赟,鲍红荣,等.“帕金森病病友会”药学服务新模式对患者依从性的影响[J].中国现代应用药学,2019,36(3):349-352.
[24] World Health Organization. World health statistics 2018:monitoring health for the SDGs [EB/OL].(2018-05-18)[2021-12-22].https://www.who.int/gho/publications/wor- ld_ health_statistics/2018/en/.
[25] 王静,张臣宇,吴迪,等.成都市社会药房慢病管理服务现状调查研究[J].中国药房,2020,31(5):622-626.
[26] 闫秀文,李智,谭敏,等.居家老年人用药依从性及影响因素分析[J].社区医学杂志,2021,19(20):1260-1266.
[27] 丁晓莉,王松,周春巧,等.家庭药师服务模式对房颤患者服用华法林的依从性及预后的影响[J].中国医药导报,2020,17(32):181-184.
[28] 吴秋惠,王鸯鸯,彭宇竹,等.基层药师慢性阻塞性肺疾病药学服务影响因素KAP研究[J].中国药师,2020,23(4):676-679.
[29] 国务院.国务院关于建立全科医生制度的指导意见[EB/OL].(2011-07-06)[2023-02-05].https://www.gov.cn/zhengce/ content/2011-07/06/content_6123.htm.
[30] 国家卫生健康委员会,教育部,财政部,等.卫生健康委 教育部 财政部 人力资源社会保障部 医保局 药监局关于印发加强医疗机构药事管理促进合理用药的意见的通知[J].中华人民共和国国务院公报,2020(18):43-46.
[31] 陆超,田侃,喻小勇,等.药师管理主体及监管制度研究[J].卫生经济研究,2021,38(8):16-18.
[32] 孙晓鸣,查良英,徐凤华,等.老龄化背景下家庭药师开展居家药学服务的探讨[J]. 中国现代医药杂志,2021, 23(11):85-89. |
|
|
|